Post-earnings recap
Reported
Thu, Aug 6, 2026
EPS actual
$2.28
EPS est.
$1.73
EPS surprise
+32.17%
1-day move
+2.60%
Halozyme Therapeutics reported strong earnings with an EPS that significantly exceeded expectations, leading to a 2.6% increase in stock price. However, revenue figures were not disclosed, leaving some uncertainty. The positive EPS surprise indicates strong performance in profitability, which may enhance investor confidence.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.28 | $1.82 | +32.17% |
| Revenue | N/A | $402M | N/A |
No transcript is on record, and the analysis is based on numerical results only.
Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing innovative therapies for patients with serious diseases. With a market cap of $11 billion, it plays a significant role in the health care sector, particularly in the development of enzyme-based treatments that enhance the delivery of biologic drugs.
Last quarter
In Q1 2026, Halozyme reported an EPS of $1.60, exceeding estimates by 9.74%. The stock rose 3.57% the following day, indicating positive market sentiment.
Management promises and guidance
EPS beat streak
2Q
EPS beat rate
88%
Avg EPS surprise
+6.80%
Avg 1-day reaction
+0.95%
Analysts are generally optimistic about Halozyme's upcoming earnings, expecting solid EPS and revenue growth. The company has a strong track record of beating earnings estimates.
Bull case
If Halozyme exceeds the consensus EPS and revenue estimates, it could signal strong demand for its products and effective cost management, potentially driving the stock higher.
Bear case
Conversely, if the company fails to meet expectations or provides weak guidance, it could raise concerns about its growth prospects and lead to a decline in stock price.
Key metrics to watch
EPS
$1.82Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating revenue.
Revenue
$402MTotal revenue is crucial for understanding the company's growth and market demand for its products.
The print will turn on these.
Q1
Will EPS exceed the consensus estimate of $1.82?
A beat on EPS would reinforce investor confidence in the company's profitability and growth trajectory.
Q2
What is the outlook for revenue growth compared to the consensus of $402M?
Revenue growth is critical for assessing the company's market position and future potential.
Est. EPS
$6.10
Est. Rev
$5.0B
Impl. Move
±5.3%
Why consensus could be wrong
The consensus may underestimate the impact of recent partnerships and product advancements, which could drive higher revenue growth than anticipated.
Supporting evidence
Halozyme's recent collaborations suggest a stronger product pipeline than reflected in current estimates.
The company has consistently beaten EPS estimates, indicating potential for continued outperformance.
Options pricing suggests a significant move, indicating that the market expects more volatility than usual.
Key risk
If revenue comes in above $415M, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
This quarter's results will be closely watched as they could indicate the company's ability to sustain growth amid market challenges.
Bull confirmed if
An EPS of $1.90 or higher would confirm strong operational performance and market demand.
Bear confirmed if
An EPS below $1.72 would raise concerns about the company's growth and profitability.
What the market is pricing for the move.
Implied Move
±15.76%
Historical Avg
±1.6%
The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.
Options are pricing ±15.8% while HALO has averaged ±1.6% over the last 8 prints — setup is pricing rich.
ATM IV
0.4%
30d HV
32.9%
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$567,660.74
5,230 sh
1 insider
Net
$567,660.74
Net selling
Most Active Insiders· 4 open-market trades
Smart-money positioning from the most recent 13F filings.
Institutional
113.09%
of float
Insider
1.09%
of float
Holders
909
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
13,271,095 sh · $1.5B
11.69%
0.1%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Halozyme beats expectations, history suggests the stock could rise by around 0.49%, confirming strong demand and effective management.
In line / cautious
If results are in line with expectations, the market may react cautiously, leading to a muted response as investors await further guidance.
Miss
A miss could lead to a decline in stock price, with historical patterns suggesting an average drop of around 1.31%.
The lines on the call that would change the story.
$567,660.74
Net selling
Recent Transactions
Oct 1, 2026 · @ $108.45
3,300 sh
$357,898.20
Oct 1, 2026 · @ $109.57
1,100 sh
$120,525.90
Oct 1, 2026 · @ $107.17
730 sh
$78,232.64
Oct 1, 2026 · @ $110.04
100 sh
$11,004.00
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.
Vanguard Capital Management LLC
5,351,312 sh · $592.9M
4.71%
1.5%
Vanguard Portfolio Management LLC
5,299,008 sh · $587.1M
4.67%
0.9%
State Street Corporation
5,179,434 sh · $573.8M
4.56%
4.9%
Invesco Ltd.
3,177,997 sh · $352.1M
2.80%
-20.8%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.